| Identification | Back Directory | [Name]
TP0903 | [CAS]
1341200-45-0 | [Synonyms]
TP0903
TP-0903
CS-1642
Dubermatinib
TP 0903;TP0903
TP-0903(Dubermatinib)
Dubermatinib(TP-0903)
2-((5-chloro-2-((4-((4-methylpiperazin-1-yl)methyl)phenyl)amino)pyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide
2-[[5-Chloro-2-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethylbenzenesulfonamide
Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- | [Molecular Formula]
C24H30ClN7O2S | [MDL Number]
MFCD28502172 | [MOL File]
1341200-45-0.mol | [Molecular Weight]
516.06 |
| Chemical Properties | Back Directory | [Melting point ]
>198°C (dec.) | [Boiling point ]
664.7±65.0 °C(Predicted) | [density ]
1.347±0.06 g/cm3(Predicted) | [storage temp. ]
Hygroscopic, -20°C Freezer, Under inert atmosphere | [solubility ]
Chloroform (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
7.60±0.10(Predicted) | [color ]
Off-White to Light Yellow |
| Hazard Information | Back Directory | [Uses]
TP-0903 is an AXL kinase inhibitor. | [Biological Activity]
axl and other tam family members are known to be involved in maintaining the mesenchymal phenotype in cancer cells. mesenchymal cells have increased invasion and migratory properties, enhanced cell survival in stressed environments, as well as increased resistance to targeted therapies. tp-0903 is a potent anti-cancer agent targeting the axl receptor tyrosine kinase. | [in vitro]
on the basis of the potency of tp-0903 in biochemical assays, its activity in cell-based studies was evaluated. tp-0903 showed extremely potent activity in cell viability assays against the pancreatic cancer cell line psn-1. more importantly, tp-0903 was evaluated for its ability to block gas6-mediated activation of axl in pancreatic cancer cells. psn-1 cells were serum-starved and then stimulated with gas6 in the presence of various concentrations of tp-0903 [1]. | [in vivo]
tp-0903 restores sensitivity to erlotinib in cell-based and preclinical animal models of cancer by reversing the mesenchymal phenotype driving resistance [2]. | [IC 50]
0.027 μm against axl | [References]
[1] mollard a, warner sl, call lt, wade ml, bearss jj, verma a, sharma s, vankayalapati h, bearss dj. design, synthesis and biological evaluation of a series of novel axl kinase inhibitors. acs med chem lett. 2011 dec 8;2(12):907-912.
[2] toleropharmaceuticals, inc–tp-0903. http://www.toleropharmaceuticals.com/tp-0903.html. |
|
|